Asaf is a synthetic, broad-spectrum antibacterial agent from the difluoroquinolone family. It has been reported to be more active in vitro than ciprofloxacin against some organisms, including staphylococci and Mycobacteria, and has a much longer plasma half-life (16 hours).
Asaf inhibits the supercoiling activity of DNA gyrase which is an enzyme essential for DNA replication thus promoting the breakage of DNA structures. It has activity against S. pneumoniae, S. aureus, H. influenzae, K. pneumoniae, M. catarrhalis and Mycobacterium spp.
Asaf is used for the treatment of the following infections due to susceptible microorganisms:
- Upper and lower respiratory tract infections including sinusitis, acute exacerbation of chronic bronchitis, community and hospital acquired pneumonia.
- Urinary tract infections including gonococcal and non-gonococcal urethritis, chancroid and other sexually transmitted diseases.
- Skin and soft tissue infections.
- Prophylactic use in different urological and ophthalmic operations.
Asaf is also used to associated treatment for these conditions: Acute Sinusitis, Chronic Obstructive Airways Disease Exacerbated, Community Acquired Pneumonia (CAP), Susceptible infections
Low plasma protein binding in serum at about 45%.
|Therapeutic Class||4-Quinolone preparations|
|Manufacturer||Asiatic Laboratories Ltd|
|Last Updated:||June 23, 2021 at 11:25 am|
Table Of contents
In patients with normal renal function the recommended daily dose is two tablets of Asaf 200 mg on first day as a loading dose, thereafter take one tablet of Asaf 200 mg every 24 hours for a total of 10 days of therapy.
The recommended daily dose of Asaf in patients with renal impairment (Creatinine clearance < 30 ml/min) is two tablets of 200 mg taken on the first day as a loading dose. Thereafter, should be taken one tablet of 200 mg every 48 hours for total of 9 days of therapy.
Asaf can be taken with or without food.
Most of the adverse events were mild to moderate in severity and transient in nature. The most frequently reported events among the Asaf treated patients with the recommended dosage are: diarrhea, nausea, headache, dyspepsia, dizziness, insomnia, abdominal pain and QTc interval prolongation.
It should be used with caution in renal diseases, gastric ulcers and with concomitant use of NSAIDs. In renal failure of third degree severity (creatinine clearance < 30 ml/min) dosage modification is recommended 400 mg on 1st day, 200 mg on 2nd and 3rd day followed by 200 mg every 48 hours. Because fluoroquinolones have been associated with tendon rupture, Asaf should be discontinued at the first sign of tendon pain. Exposure to UV radiation during treatment should be avoided.
On concomitant use with Quinidine, Sotalol, Erythromycin, Astemizole, Terfenadine, vinca alkaloids there is increased risk of arrhythmia. Salts, oxides and hydroxides of Magnesium, Aluminium and Calcium decrease absorption of Asaf.
Mean terminal elimination half-life of 20 hours (range 16-30 hours). Prolonged in patients with renal impairment (creatinine clearance <50 mL/min).
Pregnancy & Breastfeeding use
There are no adequate and well controlled studies in pregnant women. Asaf should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Asaf is contraindicated for individuals with a history of hypersensifivity and in achilles tend in its following the use of fluoroquinolone and in pregnancy and lactation. Asaf is contraindicated in patients with known QTc prolongation or in patients being treated concomitantly with medications known to produce an increase in the QTc interval and/or torsade depointes.
Use in children: Safety and effectiveness have not been established in patients below the age of 18 years.
Store at temperature below 30° C.